News

News 2016-11-13T22:07:37+00:00

Arix Bioscience appoints Giles Kerr to Board of Directors

LONDON, 17 October 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, today announces the appointment of Giles Kerr as a Non-Executive Director of the Company and chairman of the Board’s Audit Committee. The appointment is with immediate effect. Giles Kerr has 36 years’ experience in finance across a broad range of industrial [...]

October 17th, 2017|

Arix Bioscience notes positive Phase I clinical and non-clinical data from Amplyx for the treatment of life-threatening fungal infections

LONDON, 10 October 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience"), a global healthcare and life science company supporting medical innovation, is pleased to note the release of positive clinical and non-clinical data by Amplyx Pharmaceuticals (“Amplyx”), an Arix Bioscience Group Business, at IDWeek 2017, held in San Diego, CA. The data showed that Amplyx’s lead candidate APX001, a novel, broad-spectrum drug in development for [...]

October 10th, 2017|

Arix Bioscience participates in $80 million Series C financing for Autolus

LONDON, 26 September 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or “Arix”), a global healthcare and life science company supporting medical innovation, today announces that it has participated in an $80 million Series C financing round for Autolus Limited (“Autolus”), an Arix Bioscience Group Business. Autolus is a clinical-stage biopharmaceutical company focused on the development and commercialization of next-generation engineered T-cell therapies. Arix Bioscience [...]

September 26th, 2017|

Arix Bioscience plc notes positive clinical study announcements from Autolus Limited

LONDON, 18 September 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience"), a global healthcare and life science company supporting medical innovation, is pleased to note two positive press releases today by Autolus Limited (“Autolus”), an Arix Bioscience Group Business, announcing clinical progress across its portfolio. The first release today from Autolus announced the completion of the first-dose cohort of its Phase I/II study of AUTO2, [...]

September 18th, 2017|

Arix Bioscience hosts Capital Markets Meeting today

LONDON, 18 September, 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or “Arix”), a global healthcare and life science company supporting medical innovation, is today hosting its inaugural Capital Markets Meeting for investors and analysts in London. Joe Anderson, Chief Executive Officer, and Jonathan Peacock, Chairman, will provide an update on Arix Bioscience’s strategy and progress to date. The event will also include presentations from [...]

September 18th, 2017|

Arix Bioscience to Host Capital Markets Meeting in London, 18 September 2017

LONDON, 14 September, 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, will host its inaugural Capital Markets Meeting for investors and analysts in London on 18 September 2017. Dr Joe Anderson, Chief Executive Officer of Arix Bioscience, and Jonathan Peacock, Chairman of Arix Bioscience, will provide an update on the Company’s strategy [...]

September 14th, 2017|

Arix Bioscience plc announces participation at the 19th Annual Rodman & Renshaw Global Investment Conference

LONDON, 8 September 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience", or “the Company”), a global healthcare and life science company supporting medical innovation, will present at the 19th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on 10-12 September 2017 at the Lotte New York Palace Hotel in New York City, and the [...]

September 8th, 2017|

Arix Bioscience plc notes positive trial data from Verona Pharma in COPD

LONDON, 7 September 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience"), a global healthcare and life science company supporting medical innovation, is pleased to note the announcement by Verona Pharma plc (AIM: VRP) (NASDAQ: VRNA) (“Verona Pharma”), an Arix Bioscience Group Business, of positive top-line results from its Phase 2a clinical trial for RPL554 in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). The data [...]

September 7th, 2017|

Arix Bioscience plc notes the appointment of Dr Graeme Smith as CSO of Artios Pharma

LONDON, 4 September 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or the “Company”), a global healthcare and life science company supporting medical innovation, is pleased to note the announcement by Artios Pharma Ltd, an Arix Bioscience Group Business, that it has appointed Dr Graeme Smith as Chief Scientific Officer. Dr Smith has an extensive track record in early stage cancer drug discovery and development [...]

September 4th, 2017|

Arix Bioscience participates in $67 million Series C financing for Amplyx Pharmaceuticals

Series C financing to fund Phase II clinical trials of APX001, a novel antifungal agent to treat life-threatening invasive infections LONDON, 2 August, 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or “Arix”), a global healthcare and life science company supporting medical innovation, today announces that it has acquired an interest in Amplyx Pharmaceuticals (“Amplyx”) as part of an oversubscribed $67 million Series C financing [...]

August 2nd, 2017|

Arix Bioscience Half Yearly Report for the Six Months Ended 30 June 2017

Transformative period with good progress across the business LONDON, 31 July 2017: Arix Bioscience plc (LSE:ARIX) ("Arix Bioscience", "Arix" or the "Company"), a global life sciences company supporting medical innovation, today announces its financial results for the six-month period ended 30 June 2017. Highlights Successful IPO on the Main Market of the London Stock Exchange in February 2017, raising £112 million of new proceeds to use in sourcing, [...]

July 31st, 2017|

Arix Bioscience co-leads $29 million Series A financing for PreciThera, Inc.

Funding to develop novel biologics targeting orphan bone diseases into clinical trials LONDON, 27 July 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or “Arix”), a global healthcare and life science company supporting medical innovation, today announces that it has co-led an oversubscribed Series A financing round raising $29 million ($36 million CAD) for PreciThera, Inc. (“PreciThera”), a new Arix Group Business focused on developing novel [...]

July 27th, 2017|

Arix Bioscience appoints Meghan FitzGerald to Board of Directors

LONDON, 21 July 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience”, or the “Company”), a global healthcare and life science company supporting medical innovation, today announces the appointment of Meghan FitzGerald as a Non-Executive Director of the Company. The appointment is with immediate effect and she will be a member of the Board’s Audit Committee. Meghan FitzGerald is a Partner of L1 Health, with a [...]

July 21st, 2017|

Arix Bioscience leads $45 million Series B financing round into LogicBio Therapeutics

Funding to advance gene therapies targeting orphan paediatric disorders through clinical trials LONDON, 28 June, 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or the “Company”), a global healthcare and life science company supporting medical innovation, today announces that it has led an oversubscribed Series B financing round raising $45 million for LogicBio Therapeutics Inc. (“LogicBio”), a new Arix Group Business focused on breakthrough, disease-modifying [...]

June 28th, 2017|

Arix Bioscience participates in $20 million fundraise for Mitoconix Bio

Series A finance raised by high quality investor syndicate for neurodegenerative diseases therapies LONDON, 27 June, 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or the “Company”), a global healthcare and life science company supporting medical innovation, today announces that it has acquired an interest in Mitoconix Bio Ltd. (“Mitoconix Bio”) as part of an oversubscribed $20 million Series A financing round. Mitoconix Bio is [...]

June 27th, 2017|

Arix Bioscience notes Artios Pharma’s new collaboration to develop inhibitors of novel cancer targets

LONDON, 12 June, 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or the “Company”), a global healthcare and life science company supporting medical innovation, is pleased to note the announcement by Artios Pharma Ltd, an Arix Bioscience Group Business, that it has signed a research collaboration and option agreement with Masaryk University (“MU”) in the Czech Republic for the development of novel cancer treatments targeting DNA [...]

June 12th, 2017|

Arix Bioscience notes the formation of Artios Pharma’s world-leading Scientific Advisory Board

Dr Simon Boulton – Senior Group Leader at the Francis Crick Institute and VP of Scientific Strategy at Artios Dr KJ Patel – tenured Principal Investigator at the Medical Research Council Laboratory of Molecular Biology at the University of Cambridge Dr Jos Jonkers – Professor of Molecular Experimental Oncogenetics and Cancer Therapeutics, and Head of Molecular Pathology at the Netherlands Cancer Institute Dr Serena Nik-Zainal – Cancer Research UK [...]

June 8th, 2017|

Arix Bioscience to present at Jefferies 2017 Global Healthcare Conference in New York

LONDON, 31 May, 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, today announces that Joe Anderson, Chief Executive Officer of Arix Bioscience, will present at the Jefferies 2017 Global Healthcare Conference to be held on 6-8 June in New York, US. The presentation will be on Thursday, 8 June at 4pm EDT [...]

May 31st, 2017|

Arix Bioscience co-leads $45 million Series B investment round for Harpoon Therapeutics

- Funding to advance two of Harpoon’s immuno-oncology programmes into clinical trials - LONDON, 25 May, 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, today announced that Harpoon Therapeutics, a new Arix Group Business, has closed a Series B investment round raising $45 million. Arix Bioscience co-led the financing round with New [...]

May 25th, 2017|

Arix Bioscience leads $65 million Series B investment round for Iterum

- Funding pivotal Phase 3 trial for novel antibiotic sulopenem - Investment in Ireland-based company focused on developing differentiated anti-infectives aimed at combatting pathogens LONDON, 19 May, 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, today announced that Iterum, a new Arix Group Business, has closed a Series B investment round raising [...]

May 19th, 2017|

Arix Bioscience Notes Verona Pharma’s NASDAQ Global Market Listing and $80m Fundraise

LONDON, 28 April, 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, is pleased to note the announcement by Verona Pharma plc, an Arix Bioscience Group Business, that it has raised approximately $80.0 million before expenses in a successful NASDAQ listing. Verona’s global offering priced of an aggregate of 47,399,001 new ordinary shares, [...]

April 28th, 2017|

Maiden Annual Results 2016

London, UK, 28 April 2017: Arix Bioscience plc (LSE:ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, today announces its maiden results for the period ended 31 December 2016. The following financial statements refer to the period in which Arix Bioscience was a private company, prior to its initial public offering on the Main Market of the London [...]

April 28th, 2017|

US FDA authorisation for Verona Pharma to proceed with clinical investigation of RPL554 with the acceptance of investigational new drug application

LONDON, 18 April, 2017: Arix Bioscience plc (LSE:ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, is pleased to note the announcement today by Verona Pharma, in which it has a 6.6% holding, that it has received authorisation from the Food and Drug Administration to proceed with the first clinical trial of RPL554 in the US.   RPL554 [...]

April 18th, 2017|

Arix Bioscience plc, LDC and University of Leeds collaborate to develop novel therapeutics for metabolic diseases

First project from Arix’s agreement with LDC  LONDON, 20 MARCH 2017: Arix Bioscience plc (LSE:ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, has signed an agreement with the Lead Discovery Center GmbH (LDC), Max Planck Innovation GmbH (MPI), and the University of Leeds to develop new therapeutics for metabolic diseases based on the discoveries from these organisations. [...]

March 20th, 2017|

Arix Bioscience plc signs strategic agreement with Takeda

LONDON, 2 MARCH 2017: Arix Bioscience plc (LSE:ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, today announces a strategic agreement with Takeda Ventures, Inc. (“Takeda”). The agreement will maximise the complementary skills and experience of both Arix and Takeda across important therapeutic areas. The relationship brings together the unique combination of entrepreneurial business building, investing and industry [...]

March 20th, 2017|

ARIX BIOSCIENCE APPOINTS DR FRANZ B HUMER AS SENIOR INDEPENDENT DIRECTOR

LONDON, 31 OCTOBER 2016: Arix Bioscience plc (Arix Bioscience), a global healthcare and life science company supporting medical innovation, announced today that it had appointed Dr Franz B Humer as its Senior Independent Director. Dr Humer is one of the pharmaceutical industry’s most respected executives. He served as Chief Executive Officer and Chairman of Hoffmann-La Roche and Roche Holding AG over a period of 16 [...]

October 31st, 2016|

ARIX BIOSCIENCE SUPPORTS ARTIOS PHARMA, A NEW BIOTECH COMPANY FOCUSED ON DNA DAMAGE RESPONSE

LONDON, 21 SEPTEMBER 2016: Arix Bioscience PLC (Arix Bioscience), a global healthcare and life science company supporting medical innovation, announced today that it has participated, along with leading European and US healthcare investors, in a Series A financing of Artios Pharma Ltd., a new private company focused on the DNA Damage Response (DDR). Artios has announced the launch of the company, and successful completion of [...]

September 21st, 2016|

ARIX BIOSCIENCE SUPPORTS DEPIXUS, AN EARLY-STAGE COMPANY FOCUSED ON NUCLEIC ACID SEQUENCING & EPIGENETIC ANALYSIS

LONDON, JULY 25, 2016: Arix Bioscience Limited (Arix Bioscience), a global healthcare and life science company supporting medical innovation, announced today that it has provided equity capital to Depixus, an early-stage company, based in Paris, France that is developing novel technologies for combined genetic and epigenetic analysis. Arix Bioscience sources, finances and develops businesses addressing medical innovation at all stages of development. Edward Rayner, an [...]

July 26th, 2016|

ARIX BIOSCIENCE SUPPORTS INNOVATIVE RESPIRATORY DRUG COMPANY VERONA PHARMA PLC

Arix Bioscience is pleased to announce that it has participated along with renowned international healthcare investors in a placement with Verona Pharma plc, the drug development company focused on first-in-class medicines to treat respiratory diseases. Verona has announced publicly that it has successfully secured funding commitments to raise gross proceeds of approximately US$63.3 million through the placement. Verona's full announcement can be viewed here. The [...]

June 20th, 2016|

ARIX BIOSCIENCE HAS MADE $25 MILLION COMMITMENT TO LEADING THERAPEUTICS RESEARCH ACCELERATOR, BIOMOTIV

Media Release: Arix Bioscience Limited LONDON, APRIL 18, 2016: - Arix Bioscience Limited (Arix Bioscience), formerly Perceptive Bioscience Investments Limited, a global healthcare and life science company supporting medical innovation, announced today it has agreed to provide up to $25 million capital to BioMotiv LLC, a US-based therapeutic accelerator organisation providing access to pioneering science in leading universities. Arix Bioscience sources, finances and develops businesses [...]

April 18th, 2016|

ARIX SUPPORTS INNOVATIVE BIOPHARMA COMPANY, AUTOLUS

London, 3 March 2016 – ARIX SUPPORTS INNOVATIVE BIOPHARMA COMPANY, AUTOLUS Arix Bioscience, formerly Perceptive Bioscience Investments Ltd, has provided capital support to Autolus Limited (“Autolus”), a biopharmaceutical company focused on the development and commercialisation of next-generation engineered T-cell therapies for haematological and solid tumours. Alongside Woodford Investment Management LLP, the company has participated in a Series B financing round, providing £40 million of new capital to Autolus. Dr Joe Anderson, CEO of Arix Bioscience, said: ““We are delighted to be involved with a company with the potential to transform [...]

March 3rd, 2016|